By Mark Watkins Osiris Therapeutics (NASDAQ:OSIR) was upgraded by Zacks from a “sell” rating to a “hold” rating in a report released on Tuesday, Market Beat.com reports. According to Zacks, “Osiris’ second quarter 2015 results were better than expected. We are encouraged by the company’s efforts to